Prognosis of patients with acute exacerbation of combined pulmonary fibrosis and emphysema: a retrospective single-centre study

Table 2 Laboratory data at the time of acute exacerbation in patients with IPF and CPFE-UIP

Parameter	Patients with IPF (n = 41)	Patients with CPFE (n = 21)	p-value
WBC count (/mm³)	10,030 (8620–12,500)	88,810 (6460–9320)	0.0096
CRP (mg/dL)	5.5 (2.4–10.7)	5.85 (2.68–7.15)	0.466
LDH (IU/L)	352 (261–453)	289 (263–349)	0.151
KL-6 (U/mL)	1596 (1225–2525)	966 (429–1310)	< 0.001
P/F ratio (Torr)	204 (148–277)	204 (130–261)	0.417
TR-PG (mmHg)	38.0 (33.0–48.1) (n = 5)	27.8 (25.4–55.0) (n = 7)	0.871
CT pattern: peripheral or multifocal/diffuse	27/14 (65.9%/34.1%)	17/4 (89.0%/ 19.0%)	0.345

The data are expressed as median (interquartile range) or number (percentage)
IPF idiopathic pulmonary fibrosis, CPFE combined pulmonary fibrosis and emphysema, WBC white blood cell, CRP C-reactive protein, LDH lactate dehydrogenase, KL-6 Krebs von den Lungen-6, P/F ratio ratio of partial pressure arterial oxygen to fraction of inspired oxygen (PaO2/FiO2), TR-PG transtricuspid pressure gradient, CT computed tomography

ISSN: 1471-2466